CA3005102A1 - Bis-pyridazine compounds and their use in treating cancer - Google Patents

Bis-pyridazine compounds and their use in treating cancer Download PDF

Info

Publication number
CA3005102A1
CA3005102A1 CA3005102A CA3005102A CA3005102A1 CA 3005102 A1 CA3005102 A1 CA 3005102A1 CA 3005102 A CA3005102 A CA 3005102A CA 3005102 A CA3005102 A CA 3005102A CA 3005102 A1 CA3005102 A1 CA 3005102A1
Authority
CA
Canada
Prior art keywords
formula
compound
pharmaceutically acceptable
pyridazin
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3005102A
Other languages
English (en)
French (fr)
Inventor
Maurice Raymond Verschoyle Finlay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
AstraZeneca AB
Original Assignee
Cancer Research Technology Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd, AstraZeneca AB filed Critical Cancer Research Technology Ltd
Publication of CA3005102A1 publication Critical patent/CA3005102A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3005102A 2015-11-27 2016-11-25 Bis-pyridazine compounds and their use in treating cancer Abandoned CA3005102A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1520959.6A GB201520959D0 (en) 2015-11-27 2015-11-27 Bis-pyridazine compounds and their use in treating cancer
GB1520959.6 2015-11-27
PCT/EP2016/078899 WO2017089587A1 (en) 2015-11-27 2016-11-25 Bis-pyridazine compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
CA3005102A1 true CA3005102A1 (en) 2017-06-01

Family

ID=55177338

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3005102A Abandoned CA3005102A1 (en) 2015-11-27 2016-11-25 Bis-pyridazine compounds and their use in treating cancer

Country Status (17)

Country Link
US (2) US10196382B2 (enExample)
EP (1) EP3380468B8 (enExample)
JP (1) JP2018535226A (enExample)
KR (1) KR20180083426A (enExample)
CN (1) CN108349951B (enExample)
AR (1) AR106849A1 (enExample)
AU (1) AU2016360970B2 (enExample)
CA (1) CA3005102A1 (enExample)
DK (1) DK3380468T3 (enExample)
ES (1) ES2806723T3 (enExample)
GB (1) GB201520959D0 (enExample)
IL (1) IL259358A (enExample)
MX (1) MX2018006374A (enExample)
RU (1) RU2018122012A (enExample)
SG (1) SG11201803814SA (enExample)
TW (1) TW201731837A (enExample)
WO (1) WO2017089587A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106552296B (zh) 2015-09-29 2020-08-14 上海氪励铵勤科技发展有限公司 纳米粒子、其制备方法与结石取出装置及应用
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
KR20250137464A (ko) 2024-03-11 2025-09-18 이석재 숏블라스트머신의 연마재탱크

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108785305B (zh) 2011-11-21 2021-10-29 卡利泰拉生物科技公司 谷氨酰胺酶的杂环抑制剂
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
KR20160100407A (ko) * 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
CN108349951B (zh) 2020-11-13
CN108349951A (zh) 2018-07-31
AR106849A1 (es) 2018-02-21
US10577354B2 (en) 2020-03-03
AU2016360970B2 (en) 2019-11-07
GB201520959D0 (en) 2016-01-13
IL259358A (en) 2018-07-31
US20190169172A1 (en) 2019-06-06
US10196382B2 (en) 2019-02-05
TW201731837A (zh) 2017-09-16
US20170152244A1 (en) 2017-06-01
WO2017089587A1 (en) 2017-06-01
MX2018006374A (es) 2019-07-08
KR20180083426A (ko) 2018-07-20
EP3380468B8 (en) 2020-11-04
EP3380468B1 (en) 2020-05-20
RU2018122012A (ru) 2019-12-30
EP3380468A1 (en) 2018-10-03
JP2018535226A (ja) 2018-11-29
AU2016360970A1 (en) 2018-07-05
ES2806723T3 (es) 2021-02-18
SG11201803814SA (en) 2018-06-28
DK3380468T3 (da) 2020-07-27

Similar Documents

Publication Publication Date Title
US10040788B2 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
CA3005517C (en) 1,3,4-thiadiazole compounds and their use in treating cancer
US10981904B2 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
US10577354B2 (en) Bis-pyridazine compounds and their use in treating cancer
CA3005516C (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260707A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260707B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260708B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260708A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260702A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260702B (en) 1,3,4-thiadiazole compounds and their use in treating cancer

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230216